Skip to main content
. 2021 Apr 15;23(4):e24153. doi: 10.2196/24153

Table 2.

Demographic and clinical characteristics of our Kaiser Permanente Southern California patient cohort in 2017.

Characteristics Data instances associated with no asthma-related hospital visit in the succeeding year (n=200,391), n (%) Data instances associated with asthma-related hospital visits in the succeeding year (n=4353), n (%) Data instances (n=204,744), n (%)
Age (years)

≥65 35,342 (17.64) 679 (15.60) 36,021 (17.59)

18-65 109,969 (54.88) 2052 (47.14) 112,021 (54.71)

6 to <18 43,856 (21.89) 1012 (23.25) 44,868 (21.91)

<6 11,224 (5.60) 610 (14.01) 11,834 (5.78)
Gender

Female 118,013 (58.89) 2482 (57.02) 120,495 (58.85)

Male 82,378 (41.11) 1871 (42.98) 84,249 (41.15)
Race

White 124,514 (62.14) 2302 (52.88) 126,816 (61.94)

Native Hawaiian or other Pacific Islander 1910 (0.95) 42 (0.96) 1952 (0.95)

Black or African American 26,864 (13.41) 1075 (24.70) 27,939 (13.65)

Asian 18,555 (9.26) 319 (7.33) 18,874 (9.22)

American Indian or Alaska native 987 (0.49) 31 (0.71) 1018 (0.50)

Unknown or unreported 27,561 (13.75) 584 (13.42) 28,145 (13.75)
Ethnicity

Non-Hispanic 116,801 (58.29) 2410 (55.36) 119,211 (58.22)

Hispanic 78,153 (39.00) 1868 (42.91) 80,021 (39.08)

Unknown or unreported 5437 (2.71) 75 (1.72) 5512 (2.69)
Insurance

Self-paid plan 33,758 (16.85) 647 (14.86) 34,405 (16.80)

Public 64,727 (32.30) 1904 (43.74) 66,631 (32.54)

High deductible plan 24,647 (12.30) 356 (8.18) 25,003 (12.21)

Exchange (also known as marketplace) 17,677 (8.82) 269 (6.18) 17,946 (8.77)

Commercial (employer-paid) 127,724 (63.74) 2420 (55.59) 130,144 (63.56)

Other 83,108 (41.47) 1675 (38.48) 84,783 (41.41)
Number of years from the first visit related to asthma in the data set

>3 116,285 (58.03) 2616 (60.10) 118,901 (58.07)

≤3 84,106 (41.97) 1737 (39.90) 85,843 (41.93)
Asthma medication fill

Systemic corticosteroid 64,878 (32.38) 2597 (59.66) 67,475 (32.96)

Short-acting, inhaled beta-2 agonist 137,077 (68.40) 3742 (85.96) 140,819 (68.78)

Mast cell stabilizer 0 (0.00) 0 (0.00) 0 (0.00)

Long-acting beta-2 agonist 11,343 (5.66) 467 (10.73) 11,810 (5.77)

Leukotriene modifier 26,996 (13.47) 1099 (25.25) 28,095 (13.72)

Combination of long-acting beta-2 agonist and inhaled corticosteroid 28,580 (14.26) 1151 (26.44) 29,731 (14.52)

Inhaled corticosteroid 78,220 (39.03) 2586 (59.41) 80,806 (39.47)
Comorbidity

Sleep apnea 12,811 (6.39) 333 (7.65) 13,144 (6.42)

Sinusitis 29,202 (14.57) 680 (15.62) 29,882 (14.59)

Premature birth 4381 (2.19) 132 (3.03) 4513 (2.20)

Obesity 48,548 (24.23) 1190 (27.34) 49,738 (24.29)

Gastroesophageal reflux 32,462 (16.20) 797 (18.31) 33,259 (16.24)

Eczema 20,521 (10.24) 638 (14.66) 21,159 (10.33)

Cystic fibrosis 40 (0.02) 2 (0.05) 42 (0.02)

Chronic obstructive pulmonary disease 7306 (3.65) 285 (6.55) 7591 (3.71)

Bronchopulmonary dysplasia 29 (0.01) 1 (0.02) 30 (0.01)

Anxiety or depression 46,176 (23.04) 1124 (25.82) 47,300 (23.10)

Allergic rhinitis 39,849 (19.89) 1084 (24.90) 40,933 (19.99)
Smoking status

Never smoker or unknown 125,245 (62.50) 2663 (61.18) 127,908 (62.47)

Former smoker 36,026 (17.98) 717 (16.47) 36,743 (17.95)

Current smoker 39,120 (19.52) 973 (22.35) 40,093 (19.58)